Prosensa Holding B.V. (RNA) 18.65 $RNA
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25", with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ", which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company", the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares", from the NASDAQ Global Select Market ("NASDAQ". Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser", to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration", plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR", in each case, without interest thereon and less any applicable withholding taxes.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), ALXN: 123.67 (-1.96), AMGN: 169.77 (-0.36)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 9.08 (-0.06), BMRN: 95.73 (+0.54), RNA: 18.65 (unch), GSK: 44.26 (+1.28)
BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), ALXN: 123.67 (-1.96), AMAG: 23.66 (-0.05)
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)
Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), SRPT: 26.89 (+0.33)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 26.89 (+0.33), PTCT: 7.91 (+0.12), BIOD: 0.42 (unch)
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act", which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25", with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ", which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter. BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares", from the NASDAQ Global Select Market ("NASDAQ". Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so. BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser"
, to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration", plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR", in each case, without interest thereon and less any applicable withholding taxes. BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:00PM CST
BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa acquisition.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), ALXN: 123.67 (-1.96), AMGN: 169.77 (-0.36)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 9.08 (-0.06), BMRN: 95.73 (+0.54), RNA: 18.65 (unch), GSK: 44.26 (+1.28)
BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
GlobeNewswire - Thu Jan 15, 7:59AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa's outstanding shares pursuant to the initial offering period for the tender offer. BioMarin also announced that it has commenced a subsequent offering period to provide Prosensa shareholders who have not yet tendered their shares the opportunity to do so. The subsequent offering period is scheduled to expire at 6:00 p.m., New York City time, on January 29, 2015.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:10PM CST
BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II pivotal study on Batten disease candidate, BMN 190.
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), ALXN: 123.67 (-1.96), AMAG: 23.66 (-0.05)
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
GlobeNewswire - Tue Jan 13, 7:56AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa.
RNA: 18.65 (unch)
Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage biotechnology company primarily focused on developing therapies to treat Duchenne muscular dystrophy, or DMD, tumbled 15% in December according to data from ...
BMRN: 95.73 (+0.54), RNA: 18.65 (unch), SRPT: 26.89 (+0.33)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 26.89 (+0.33), PTCT: 7.91 (+0.12), BIOD: 0.42 (unch)
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"
, which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa. BMRN: 95.73 (+0.54), RNA: 18.65 (unch)
